Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Fiche publication
Date publication
mai 2020
Journal
Journal of cancer research and clinical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Mme TRUNTZER Caroline, Dr FAVIER Laure, Dr FUMET Jean-David
Tous les auteurs :
Aarnink A, Fumet JD, Favier L, Truntzer C, Ghiringhelli F
Lien Pubmed
Résumé
Checkpoint inhibitors (CKI) targeting PD-1 or PD-L1 are major therapies for the treatment of non-small cell lung cancer (NSCLC). Despite numerous studies of biological biomarkers, we currently lack a marker to predict CKI primary resistance. The aim of this study was to isolate clinical markers associated with the absence of efficacy of CKI used as monotherapy in NSCLC.
Mots clés
Biomarkers, Checkpoint inhibitors, Immunotherapy, Non-small cell lung cancer
Référence
J. Cancer Res. Clin. Oncol.. 2020 May 30;: